COMMUNIQUÉS West-GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
RESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired [...]
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
03/04/2026
Study will highlight novel iNKT cell-based combinations in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response NEW YORK, April 03, [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Déclaration d'actions et de droits de vote de la société Valneva SE - Mars 2026
03/04/2026
VALNEVA Déclaration d’actions et de droits de vote 31 mars 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : Îlot [...]
Declaration of shares and voting rights of Valneva SE – March 2026
03/04/2026
VALNEVA Declaration of shares and voting rights March 31, 2026 __________________________________________________________________________________________ Company name: VALNEVA Registered office: Îlot Saint-Joseph [...]
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
03/04/2026
PARIS, FRANCE, 3 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) announces that Beech Tree — which directly and indirectly holds 26.03% of Ipsen S.A.’s share capital and 33.05% of its voting rights — has obtained from [...]
Ipsen annonce l’obtention par Beech Tree d’une dérogation à l’obligation de déposer une offre publique
03/04/2026
PARIS, FRANCE, 3 AVRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce que Beech Tree - qui détient directement et indirectement 26,03 % du capital et 33,05 % des droits de vote d'Ipsen S.A. - a obtenu de l’Autorité [...]
Cacao Bliss Claims Evaluated: The Natural GLP-1 Superfood Alternative, Earth Echo's Chocolate Drink Mix for Weight Loss
03/04/2026
A 2026 informational overview of Earth Echo Foods' ceremonial-grade cacao formulation, GLP-1 research context referenced in chocolate-based weight management discussions, ingredient disclosures, blue zone longevity [...]
Minerva Announces Leadership Transition
02/04/2026
Jim O’Connor joins as Chief Business Officer and General Counsel BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026
02/04/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 13 newly- [...]
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
02/04/2026
FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of April 1, 2026 [...]
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
02/04/2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients [...]
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
02/04/2026
HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug [...]
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
02/04/2026
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data Collaboration will expand Regeneron’s world- [...]
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
02/04/2026
ALISO VIEJO, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to [...]
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

Pages